Allspring Global Investments Holdings LLC Sells 2,280 Shares of Charles River Laboratories International, Inc. $CRL

Allspring Global Investments Holdings LLC decreased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.1% in the first quarter, HoldingsChannel reports. The institutional investor owned 1,993,316 shares of the medical research company’s stock after selling 2,280 shares during the period. Charles River Laboratories International comprises approximately 0.6% of Allspring Global Investments Holdings LLC’s holdings, making the stock its 25th largest position. Allspring Global Investments Holdings LLC’s holdings in Charles River Laboratories International were worth $348,631,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of Charles River Laboratories International by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after acquiring an additional 47,432 shares during the period. Invesco Ltd. grew its stake in Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after purchasing an additional 1,446,972 shares in the last quarter. State Street Corp grew its stake in Charles River Laboratories International by 2.2% in the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock worth $373,364,000 after purchasing an additional 40,535 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Charles River Laboratories International by 27.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,442,224 shares of the medical research company’s stock worth $287,703,000 after purchasing an additional 311,319 shares during the period. Finally, Geode Capital Management LLC raised its position in Charles River Laboratories International by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock valued at $254,186,000 after purchasing an additional 9,756 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Trading Up 0.4%

Shares of NYSE:CRL opened at $229.08 on Friday. Charles River Laboratories International, Inc. has a 12-month low of $144.26 and a 12-month high of $237.86. The business’s fifty day simple moving average is $191.82 and its 200-day simple moving average is $186.50. The company has a market capitalization of $11.03 billion, a PE ratio of -60.93, a P/E/G ratio of 2.54 and a beta of 1.40. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same period in the prior year, the business posted $2.34 EPS. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the transaction, the director directly owned 31,596 shares in the company, valued at approximately $7,109,100. The trade was a 70.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.30% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. CLSA upgraded Charles River Laboratories International from a “hold” rating to an “outperform” rating and raised their price target for the company from $167.00 to $219.00 in a research note on Friday, May 29th. Morgan Stanley lifted their price objective on Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Robert W. Baird set a $213.00 price objective on shares of Charles River Laboratories International in a research note on Friday, May 8th. Finally, Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $220.75.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.